High serum serotonin as a favorable prognostic factor for patients with hepatocellular carcinoma

Takaharu Kawai
Nihon University

Yutaka Midorikawa (mido-tky@umin.ac.jp)
Nihon University

Aya Nonaka
University of Tokyo

Shingo Tsuji
University of Tokyo

Motoaki Seki
Chiba University

Genta Nagae
University of Tokyo

Tadatoshi Takayama
Nihon University

Research Article

Keywords: serotonin, platelet, hepatocellular carcinoma, prognostic factor

DOI: https://doi.org/10.21203/rs.3.rs-119588/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Serotonin contributes to liver cancer progression; however, it also plays a pivotal role in liver regeneration after partial resection. This study aims to elucidate whether high serum serotonin is a prognostic factor for patients with hepatocellular carcinoma (HCC).

Methods

We measured the pre-operation serum serotonin level of patients with HCC. Based on the median value of serum serotonin, patients were divided into the high serotonin group and the low serotonin group. The survival rates after operation were compared between the two groups.

Results

The median serum serotonin level for 176 patients was 90.5 ng/mL (range, 1.0 – 399.5); 88 patients with serum serotonin level $\geq$ 90.5 were allocated to the high serotonin group and 88 patients to the low serotonin group. Histological findings showed that tumor stage was not different between the two groups. After a median follow-up period of 3.2 years (range, 0.9 – 7.4), median overall survival was 6.6 years (95% confidence interval [CI], 5.7–NA) and 5.7 years (95% CI, 3.5–NA) in the high and the low serotonin groups, respectively ($P=0.042$). The median recurrence-free survival of patients in the high serotonin group (2.2 years [95% CI, 1.7–3.2]) tended to be longer than that of patients in the low serotonin group (2.0 years [1.0–2.2]) ($P=0.091$). The independent variables for overall survival were the high serum serotonin level ($P=0.049$) and des-gamma-carboxy prothrombin level ($P=0.032$).

Conclusions

High serum serotonin could be a favorable prognostic factor for HCC patients undergoing liver resection.

Trial registration

The study was approved (protocol number: 131) by the institutional review boards of Nihon University on December 15 in 2011.

Background

Serotonin is produced in the enteric nervous system of the gastrointestinal tract, stored in the platelets, and has multifunctional roles such as modulating blood coagulation, vasoconstriction, and pain threshold [1, 2]. This molecule is also involved in diverse types of pathological conditions of the liver; it works as a mediator of liver regeneration after partial resection or ischemic injury [3]. On the other hand, serotonin contributes to the development of liver diseases such as fibrosis [4], cholestasis [5], non-alcoholic steatohepatitis [6], and viral hepatitis [7].
It was reported that serotonin receptors are overexpressed in the advanced stages of hepatocellular carcinoma (HCC) and the blocking the receptors consistently decreased proliferation of liver cancer cells [8]. Serotonin was also shown to facilitate tumor growth of primary liver cancers such as cholangiocarcinoma and HCC via signaling pathway activation [9, 10]. Finally, serotonin was shown to be available as a diagnostic biomarker for HCC in clinical practice [11, 12] and in a mouse model [13]. However, the assertion that high serum serotonin can affect the surgical outcomes in patients undergoing resection for HCC is still controversial [14 – 16], in part due to the multifunctional physiology of serotonin in the liver.

In this study, we measured the serum serotonin level and platelet count of patients who underwent resection for HCC, and investigated whether serotonin released from the platelets affected the surgical outcomes of patients with HCC.

Methods

Patients

Patients with HCC, who underwent liver resection between 2011 and 2014 in the Department of Digestive Surgery, Nihon University School of Medicine, were recruited in this study. Each participant provided written informed consent, and the study was approved (protocol number: 131) by the institutional review boards of Nihon University. All the clinical investigations were conducted according to the principles mentioned in the Declaration of Helsinki. Surgical specimens were immediately cut into small pieces after resection, snap frozen in liquid nitrogen, and stored at −80 °C.

Sample preparation

Peripheral blood was preoperatively obtained after induction of anesthesia, put in a vacutainer tube without anti-coagulants coated, and centrifuged at 1,000 g at room temperature for 15 min. The resulting supernatant was labeled as serum and stored at −20 °C.

Quantification of serum serotonin

Serum serotonin level was measured via Serotonin ELISA Kit (ENZO Life Sciences; reference range, 0.5 – 500 ng/mL) according to the manufacturer's protocols. Based on the median value of serum serotonin, patients were divided into the high serotonin group and the low serotonin group.

Inclusion and exclusion criteria

Only the patients who were histologically diagnosed as HCC were included. The following patients were excluded; patients without HCC by pathological findings after operation, those who had received treatments for other types of cancer within 3 years, or those who underwent non-curative liver resection were excluded from this study.
Tumor stage based on the General Rules for the Clinical and Pathological Study of Primary Liver Cancer was determined by the pathological diagnosis after operation [17].

**Surgical procedures**

Open liver resection was performed in all patients according to the criteria based on liver function [18]. Curative resection was defined as the complete removal of recognizable viable HCC diagnosed preoperatively or intraoperatively with macroscopically tumor-free surgical margins. Postoperative complications were stratified according to the Clavien-Dindo classification [19], which defines morbidities as complications with a score of ≥ 3a.

**Follow-up after operation**

All patients were followed for postoperative recurrence as described previously [20]. Briefly, tumor marker levels, including the levels of alpha-fetoprotein and des-gamma-carboxy prothrombin (DCP), were measured, and imaging studies including computed tomography and ultrasonography were performed every three months in all patients. Recurrence was diagnosed by dynamic computed tomography and/or magnetic resonance imaging. The date of recurrence was defined as the date of examination when the recurrent HCC was noted.

**Statistical analysis**

Fisher's exact test, Student's t-test, and Wilcoxon rank-sum test were used to assess the statistical significance of the data collected from the patients. The correlation coefficient was calculated using the Spearman test. Survival curves were generated using the Kaplan–Meier method and compared by the log-rank test. Prognostic factors for survival were identified using the Cox proportional hazards regression model. A P-value of less than 0.10 was set as the cut-off value for elimination. The following 18 variables, considered as potential confounders, were examined: age (≥ 70 versus < 70 years), sex, positive for hepatitis B or C virus, alcohol abuse, diabetes mellitus, platelet count (≥ 15 × 10⁴ versus < 15 × 10⁴/mL), serotonin (≥ 90.5 versus < 90.5 ng/mL), Child-Pugh score (5 vs ≥ 6), indocyanine green clearance rate at 15 minutes (ICGR15) (≥ 15 versus < 15%), esophageal varices, serum alpha-fetoprotein level (≥ 100 versus < 100 ng/mL), serum DCP level (≥ 100 versus < 100 mAU/mL), tumor size (≥ 3.0 versus < 3.0 cm), tumor number (single versus multiple), poorly differentiated, tumor thrombus, and liver cirrhosis [21, 22]. Statistical significance was set at P < 0.05. All statistical analyses were performed using the JMP 12.0.1 statistical software package (SAS Institute Inc, Cary, NC).

**Results**

**Serum serotonin level**

The median of the preoperative serum serotonin level and platelet count from 176 HCC patients were 90.5 ng/mL (range, 1.0 – 399.5) and 12.5 × 10⁴/mL (range; 3.2 × 10⁴ – 68.6 × 10⁴), respectively (Fig. 1a). Furthermore, 88 patients with serum serotonin ≥ 90.5 ng/mL were defined as the high serotonin group.
and other 88 patients as the low serotonin group (Table 1). Patient background was not different between the two groups. The serum serotonin level was not correlated with the platelet count (coefficients of determination $[R^2]$ between the serum serotonin level and the platelet count was 0.013) (Fig. 1b).

Table 1
Patient background

|                  | High serotonin (n = 88) | Low serotonin (n = 88) | $P$ value |
|------------------|-------------------------|------------------------|-----------|
| Age, years       | 66 (31 − 85)           | 69 (40 − 84)           | 0.136     |
| Sex, male        | 70 (79.5)               | 69 (78.4)              | 1.000     |
| Hepatitis B      | 20 (22.7)               | 19 (21.5)              | 1.000     |
| Hepatitis C      | 32 (36.3)               | 45 (51.1)              | 0.067     |
| Alcoholic        | 30 (34.0)               | 28 (31.8)              | 0.872     |
| Diabetes mellitus| 29 (32.9)               | 25 (28.4)              | 0.624     |
| Platelet count   | 13.6 (5.4 − 54.0)       | 12.9 (3.2 − 68.6)      | 0.255     |
| Child-Pugh, 5    | 68 (77.2)               | 60 (68.1)              | 0.236     |
| ICGR15           | 14.4 (3.3 − 38.7)       | 13.9 (3.1 − 38.7)      | 0.883     |
| Varices          | 25 (28.4)               | 19 (21.5)              | 0.446     |
| Alpha-fetoprotein| 15 (1 − 31,723)         | 11 (1 − 154,356)       | 0.572     |
| DCP              | 48 (1 − 75,000)         | 73 (6 − 75,000)        | 0.368     |

Data are presented as n (%) or median (range). ICGR15, indocyanine green clearance rate at 15 minutes; DCP, des-gamma-carboxy prothrombin.

Operative data

Operative data and complication rates were not different between the two groups (Table 2). Eight patient (4.5%) in the two groups underwent reoperation for intra-abdominal bleeding (four patients), portal venous thrombus (two patients), bile leakage (one patients), and intra-abdominal abscess (one patient). There was no operative death in this series. Histological findings showed that tumor stage including tumor number, size, differentiation grade, vascular invasion, and tumor stage and liver status were also not different between the two groups.
Table 2
Operative data

|                         | High serotonin (n = 88) | Low serotonin (n = 88) | P value |
|-------------------------|-------------------------|------------------------|---------|
| Operative data          |                         |                        |         |
| Operative time, min     | 314 (131 − 685)         | 317 (154 − 722)        | 0.517   |
| Clamp time, min         | 58 (0 − 385)            | 64 (0 − 227)           | 0.226   |
| Bleeding, mL            | 278 (22 − 1,593)        | 318 (26 − 3,887)       | 0.435   |
| Transfusion             | 2 (2.2)                 | 4 (4.5)                | 0.682   |
| Complications           |                         |                        |         |
| Overall                 | 34 (38.6)               | 23 (26.1)              | 0.106   |
| Morbidity               | 23 (26.1)               | 19 (21.5)              | 0.596   |
| Re-operation            | 4 (4.5)                 | 4 (4.5)                | 1.000   |
| Operative death         | 0                       | 0                      | 1.000   |
| Hospital stay, days     | 10 (6 − 32)             | 10 (7 − 20)            | 0.976   |
| Pathology               |                         |                        |         |
| No. of tumor, multiple  | 25 (28.4)               | 20 (22.7)              | 0.166   |
| Tumor size              | 3.1 (1.2 − 18.0)        | 3.0 (1.2 − 16.5)       | 0.371   |
| Differentiation grade, Poorly | 6 (6.8) | 10 (11.3) | 0.188 |
| Vascular invasion       | 23 (26.1)               | 27 (30.6)              | 0.867   |
| Tumor stage, I / II     | 66 (75.0)               | 67 (76.1)              | 1.000   |
| Cirrhosis               | 31 (35.2)               | 38 (43.1)              | 0.188   |

Data are presented as n (%) or median (range).

Survival

During a median follow-up period of 3.2 years (range, 0.9 − 7.4), a total of 108 patients (61.3%) had recurrence: 96 patients (88.8%) in the remnant liver, and 7 patients (6.4%) in distant sites, and 5 patients (4.6%) in both intra and extrahepatic sites) (Table 3). Furthermore, 55 patients (31.2%) died after HCC recurrence. Treatments for recurrent HCC were not different between the two groups.
Table 3
Treatment for recurrence

|                         | High serotonin (n = 52) | Low serotonin (n = 56) | P value |
|-------------------------|-------------------------|------------------------|---------|
| Recurrent sites         |                         |                        |         |
| Intrahepatic            | 46 (88.4)               | 50 (89.2)              | 0.904   |
| at stump                | 14 (30.4)               | 11 (22.0)              |         |
| Distant sites           | 4 (7.6)                 | 3 (5.3)                |         |
| Both                    | 2 (3.8)                 | 3 (5.3)                |         |
| Treatments              |                         |                        |         |
| Second resection        | 18 (34.6)               | 16 (28.5)              | 0.910   |
| TACE/TAI                | 31 (59.6)               | 37 (66.0)              |         |
| Chemotherapy            | 1 (1.9)                 | 2 (3.5)                |         |
| Radiation therapy       | 1 (1.9)                 | 1 (1.7)                |         |
| None                    | 1 (1.9)                 | 1 (1.7)                |         |

Data are presented as n (%). TACE, transcatheter arterial chemoembolization; TAI, transcatheter arterial infusion.

The median overall survival periods were 6.6 years (95% confidence interval [CI], 5.7–NA) and 5.7 years (95% CI, 3.5–NA; P = 0.042) in the high and the low serotonin groups, respectively (Fig. 2a). The median recurrence-free survival of patients in the high serotonin group tended to be longer than that of the patients in the low serotonin group (2.2 years [95% CI, 1.7–3.2] vs. 1.7 years [1.0–2.2], P = 0.091) (Fig. 2b). The 5-year overall survival rates were 71.7% and 53.9%, and the 5-year recurrence-free survival rates were 27.1% and 19.8% in the high and the low serotonin groups, respectively.

The overall survival of patients with advanced tumor (stage III/IV) (hazard ratio [HR], 1.85, 95% CI, 1.04–3.18, P = 0.034) and/or liver cirrhosis (P = 0.014) were significantly shorter. The independent variables for overall survival were the high serum serotonin level (HR, 0.58, 95% CI, 0.34–0.99, P = 0.046) and DCP level (P = 0.032) (Table 4). High serotonin level (HR, 0.31, 95% CI, 0.07–0.98, P = 0.042) and DCP level (P = 0.037) were significant variables by univariate analysis when treated as a continuous variable.
Table 4
Prognostic factors for survival

| Variables            | Univariate          |         | Multivariate        |         |
|----------------------|---------------------|---------|---------------------|---------|
|                      | Hazard ratio        | P value | Hazard ratio        | P value |
| Age                  | 1.13 (0.67 - 1.94)  | 0.630   |                     |         |
| Sex                  | 0.84 (0.46 - 1.64)  | 0.610   |                     |         |
| Hepatitis B          | 1.21 (0.61 - 2.22)  | 0.563   |                     |         |
| Hepatitis C          | 1.25 (0.74 - 2.10)  | 0.391   |                     |         |
| Alcohol              | 1.50 (0.87 - 2.55)  | 0.137   |                     |         |
| Diabetes Mellitus    | 0.94 (0.52 - 1.65)  | 0.853   |                     |         |
| Platelet count       | 0.67 (0.37 - 1.16)  | 0.160   |                     |         |
| Serotonin            | 0.56 (0.32 - 0.95)  | 0.032   | 0.58 (0.34 - 0.99)  | 0.046   |
| Child-Pugh           | 2.19 (1.28 - 3.72)  | 0.004   | 1.72 (0.95 - 3.14)  | 0.072   |
| ICGR15               | 2.19 (1.28 - 3.83)  | 0.003   | 1.36 (0.69 - 2.68)  | 0.370   |
| Varices              | 1.95 (1.11 - 3.34)  | 0.020   | 1.41 (0.70 - 2.86)  | 0.328   |
| Alpha-fetoprotein    | 1.50 (0.80 - 2.65)  | 0.194   |                     |         |
| DCP                  | 1.75 (1.03 - 3.00)  | 0.037   | 1.84 (1.05 - 3.25)  | 0.032   |
| No. of tumor         | 1.77 (1.01 - 3.03)  | 0.044   | 1.64 (0.92 - 2.84)  | 0.090   |
| Tumor size           | 1.45 (0.84 - 2.59)  | 0.174   |                     |         |
| Differentiation grade| 0.79 (0.35 - 1.53)  | 0.520   |                     |         |
| Vascular invasion    | 1.03 (0.55 - 1.82)  | 0.916   |                     |         |
| Liver cirrhosis      | 1.92 (1.13 - 3.29)  | 0.014   | 1.39 (0.71 - 2.70)  | 0.328   |

Data are presented with 95% confidence Interval. ICGR15, indocyanine green clearance rate at 15 minutes; DCP, des-gamma-carboxy prothrombin.

**Discussion**

Our data showed that surgical outcomes of HCC patients with high serum serotonin level were favorable. Therefore, preoperative serum serotonin could be available as the prognostic marker for patients undergoing resection for HCC.

Consistent with the present data, both serum serotonin and intra-platelet serotonin levels were lower in patients with early recurrence of HCC, although the cohort of patients was small (n = 40) [14]. Conversely,
recurrence-free survival of patients with high intra-platelet serotonin levels (>134 ng/mL) was significantly shorter, despite severe morbidities being associated with low intra-platelet serotonin levels (<73 ng/mL) [15]. Furthermore, another study reported that lower serum and intra-platelet serotonin levels were negatively correlated with both overall survival and recurrence-free survival [16]. This discrepancy of relations between survival and the serotonin levels could be attributed to the multifunctional roles of serotonin [23, 24].

Serotonin was reported to contribute to liver cancer progression via serotonin receptors, HTR1B and HTR2B, in tumors [8], by activating Wnt/β-catenin pathways [9], or by regulating YAP gene expression [10], and serotonin receptors could be potential therapeutic targets for HCC [8 – 10]. In other types of cancer such as prostate, lung, colorectal, and bile duct cancer, serotonin was involved in cancer cell migration, invasiveness, and metastatic processes through 5HT1A receptor [25]. In human, serotonin in the tumor may act on the cell growth, differentiation of neighboring cells through paracrine mechanisms, and may facilitate tumor recurrence and metastasis, correlated with shorter survivals [26].

On the other hand, platelets support regeneration of the remnant liver after resection [27, 28], and platelet-derived serotonin is a potent mitogen for hepatocytes, and plays a critical role in liver regeneration after partial resection, both in clinical practice [29] and in mouse models [3, 30, 31]. Furthermore, serotonin administration with hexoses or ionizing radiation synergistically and negatively affect the tumor growth [32, 33]. Thus, the effect of serotonin on tumor progression was controversial even in the experimental level.

Owing to the contradictory effects of serotonin, which balance between liver regeneration and liver cancer progression, it is still controversial whether high serum serotonin or intra-platelet serotonin levels are favorable or unfavorable for the survivals of patients after resection for HCC. Tumor stage including number, size, differentiation grade, and vascular invasion were not different between the two groups. Given that liver regeneration was prompted by high serotonin content even under cirrhotic conditions [31] and that most patients had liver cirrhosis or fibrosis in this cohort, the functional role of serotonin for liver regeneration was superior to that for cancer progression in this study.

We previously reported that high platelet count (≥ 20 × 10⁴/mL) was a poor prognostic marker for HCC patients without cirrhosis. Given that most of serotonin is synthesized in the enterochromaffin cells of the gastrointestinal tract and is subsequently stored and transported by platelets [34], we hypothesized that high serum serotonin was associated with poor survival rates of HCC patients. However, serum serotonin concentrations were not correlated with platelet count and the present study showed opposite results. Therefore, we assumed that poor prognosis with high platelet count in HCC patients without cirrhosis was due to the other growth factors such as platelet-derived growth factor, transforming growth factor-β, and hepatocyte growth factor which are secreted by platelets, and not due to serotonin.

Serotonin level and DCP were the independent factors for overall survival in this study. Both liver function and tumor status are the prognostic factors for HCC, and consistent with the many previous reports,
Child-Pugh and number of tumor had the marginal $P$ value in the multivariate analysis. Therefore, serotonin which might have pivotal role in liver regeneration and lead to the preservation of liver function was acceptable as one of independent factors for overall survival.

There were several limitations in this study. First, this cohort was limited to the patients who underwent liver resection, and serotonin plays a pivotal role in liver regeneration and favorably affected the patient survivals. Therefore this result does not apply to all HCC patients undergoing other types of treatments such as radiofrequency ablation, transcatheter arterial chemoembolization, and chemotherapies, which were not accompanied with liver regeneration. Second, serotonin receptors of HCC were not estimated in this series. Given that increased expression of serotonin receptors were negatively associated with the survivals of HCC patients [8, 9], the effects of serotonin in those patients should have been evaluated by serum serotonin level and expression of its receptors in the tumor. Third, only the serum serotonin level, not plasma or intra-platelet serotonin, was measured in this study. However, serum, plasma, and intraplatelet serotonin levels were nearly same [16], only one type of serotonin level from blood may predict the prognosis of HCC patients. Finally, serotonin level of healthy patients were not measured in this study. Compared to the healthy patient data using Serotonin ELISA Kit which was used in this study, however, we found that serotonin level of HCC patients in this study were apparently higher.

**Conclusions**

A high serum serotonin level was associated with longer survival of patients undergoing resection for HCC. This result was probably due to the positive role of serotonin in liver regeneration, and it showed that serotonin is available to predict the prognosis of the patient after surgery. However, serotonin plays a pivotal role in activating liver cancer progression via its receptors; therefore, two different aspects of this molecule should be estimated, both at the serum level as well as at the receptor level in the future studies.

**Abbreviations**

HCC  
hepatocellular carcinoma  
DCP  
des-gamma- carboxy prothrombin  
ICGR15  
indocyanine green clearance rate at 15 minutes

**Declarations**

**Ethics approval and consent to participate**

Each participant provided written, informed consent, and this study was approved by the institutional review board of Nihon University (protocol number: 131).
Consent for publication

Not applicable

Availability of data and materials

Data and materials analyzed in this study are not available due to the protection of individual privacy, but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by AMED under Grant Number JP20hk0102049 The funding body supported the data collection used in this study. The funding body has no role in the design of the study and analysis and interpretation of data and in writing the manuscript.

Authors’ contributions

TK and YM acquired the clinical data and wrote the initial draft of the manuscript; YM designed the study; TT conceived of the study, and participated in its design and coordination and helped to draft the manuscript; AN, MS, and GN acquired the experimental data; ST performed statistical analysis. All authors have read and approved the final version of the manuscript.

Acknowledgements

Not applicable

References

[1] Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs. 2003; 3:149–62.

[2] Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132:397–414.

[3] Lesurtel M, Graf R, Aleil B, Tian Y, Jochum W, Gachet C, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006; 312:104–7.

[4] Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006; 169:861–76.
[5] Jang JH, Rickenbacher A, Humar B, Weber A, Raptis DA, Lehmann K, et al. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation. Hepatology. 2012; 56:209–18.

[6] Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008; 68:5152–8.

[7] Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med. 2008; 14:756–61.

[8] Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild P, DeOliveira ML, et al. Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res. 2012; 18:5902–10.

[9] Fatima S, Shi X, Lin Z, Chen G, Pan X, Wu JC, et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing beta-catenin. Mol Oncol. 2016; 10:195–212.

[10] Liu S, Miao R, Zhai M, Pang Q, Deng Y, Liu S, et al. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. Oncotarget. 2017; 8:47412–24.

[11] Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, et al. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Eur J Gastroenterol Hepatol. 2016; 28:599–605.

[12] Mamdouh F, Abdel Alem S, Abdo M, Abdelaal A, Salem A, Rabiee A, et al. Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. J Interferon Cytokine Res. 2019; 39:780–5.

[13] Abdel-Hamid NM, Shehata DE, Abdel-Ghany AA, Ragaa A, Wahid A. Serum serotonin as unexpected potential marker for staging of experimental hepatocellular carcinoma. Biomed Pharmacother. 2016; 83:407–11.

[14] Aryal B, Shimizu T, Kadono J, Furoi A, Komokata T, Kitazono I, et al. Post-Resection Exhaustion of Intra-Platelet Serotonin: Also an Indicator of Early Hepatocellular Carcinoma Recurrence? J Cancer. 2017; 8:3984–91.

[15] Padickakudy R, Pereyra D, Offensperger F, Jonas P, Oehlberger L, Schwarz C, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol. 2017; 67:1243–52.

[16] Shu B, Wang S, Deng Y, Zhai M, Liu S. Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe? J Hepatol. 2018;68:1333–4.

[17] Kudo M, Kitano M, Sakurai T, Nishida N. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding
Achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015; 33: 765–70.

[18] Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993; 9:298–304.

[19] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240:205–13.

[20] Midorikawa Y, Takayama T, Higaki T, Nakayama H, Yamamoto M, Ariizumi S, et al. Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy Jpn J Clin Oncol. 2016; 46:1102–7.

[21] Yagi R, Midorikawa Y, Moriguchi M, Nakayama H, Aramaki O, Yamazaki S, e al. Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria. Surgery. 2018; 163: 1250–6.

[22] Yamagishi S, Midorikawa Y, Nakayama H, Higaki T, Moriguchi M, Aramaki O, et al. Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Hepatol Res. 2019; 49: 432–40.

[23] Lesurtel M, Soll C, Humar B, Clavien PA. Serotonin: a double-edged sword for the liver? Surgeon. 2012; 10:107–13.

[24] Papadimas GK, Tzirogiannis KN, Mykoniasi MG, Grypioti AD, Manta GA, Panoutsopoulos GI. The emerging role of serotonin in liver regeneration. Swiss Med Wkly. 2012; 142:w13548.

[25] Dizeyi N, Hedlund P, Bjartell A, Tinzi M, Tasken KA, Abrahamsson PA. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol. 2011; 29: 436−45.

[26] Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009; 11; R81.

[27] Han S, Park HW, Song JH, Gwak MS, Lee WJ, Kim G, et al. Association Between Intraoperative Platelet Transfusion and Early Graft Regeneration in Living Donor Liver Transplantation. Ann Surg. 2016; 264:1065−72.

[28] Yamazaki S, Takayama T, Mitsuka Y, Aoki M, Midorikawa Y, Moriguchi M, et al. Platelet recovery correlates parenchymal volume recovery after liver resection. Hepatol Res. 2020; 50:620−8.

[29] Starlinger P, Assinger A, Haegel S, Wanek D, Zikeli S, Schauer D, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology. 2014; 60:257–66.

[30] Furrer K, Rickenbacher A, Tian Y, Jochum W, Bittermann AG, Käch A, et al. Serotonin reverts age-related capillarization and failure of regeneration in the liver through a VEGF-dependent pathway. Proc Natl Acad Sci U S A. 2011; 108:2945–50.
[31] Nagao Y, Akahoshi T, Kamori M, Uehara H, Hashimoto N, Kinjo N, et al. Liver regeneration is promoted by increasing serotonin content in rat liver with secondary biliary cirrhosis. Hepatol Res. 2011; 41:784−94.

[32] Orvoine RH. Influence of various hexoses and vasoactive agents on osmotically induced oncolysis. Cancer Res. 198;41: 5044−8.

[33] Müller K, Gilbertz KP, Viktor Meineke V. Serotonin and ionizing radiation synergistically affect proliferation and adhesion molecule expression of malignant melanoma cells. J Dermatol Sci. 2012; 68: 89−98.

[34] Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Cell Mol Life Sci. 2008; 65:940−52.